{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:13:32Z","timestamp":1790684012030,"version":"4.1.0"},"reference-count":31,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/501100005788","name":"medizinische universit\u00e4t wien","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005788","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ther Adv Med Oncol"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:p>Mantle cell lymphoma (MCL) remains an incurable B-cell malignancy despite major advances in its therapeutic management. While Bruton tyrosine kinase inhibitors (BTKi) and, more recently, CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy have significantly improved outcomes in relapsed or refractory MCL, relapse after CAR-T therapy is associated with a dismal prognosis and represents a major therapeutic challenge. Here, we report the case of a 43-year-old male diagnosed with stage IV common-type MCL, who achieved long-term complete remission (CR) after treatment with polatuzumab vedotin, rituximab, and bendamustine (Pola-R-Benda) following relapse after CAR-T therapy. The patient had previously received standard first-line immunochemotherapy (R-CHOP alternating with R-DHAP) and autologous stem-cell transplantation, resulting in durable CR, followed by ibrutinib at first relapse in 2017 with sustained remission until 2021. Eleven months after CAR-T therapy with brexucabtagene autoleucel, the patient experienced systemic relapse. Enrollment into a Pola-R-Benda clinical protocol resulted in complete metabolic remission after three cycles, confirmed by positron emission tomography\/computer tomography. Treatment was well tolerated except for mild grade 2 diarrhea. The patient remains in ongoing CR &gt;20\u2009months after initiation of Pola-R-Benda. To our knowledge, this is among the first reports of long-term remission with Pola-R-Benda following CAR-T failure in MCL, suggesting that antibody-drug conjugate-based therapy may represent an effective salvage option in this highly refractory clinical setting.<\/jats:p>","DOI":"10.1177\/17588359261472319","type":"journal-article","created":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T09:29:12Z","timestamp":1785922152000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Long-term complete remission following treatment with polatuzumab vedotin, rituximab, and bendamustine in a patient with mantle cell lymphoma relapsing after CAR-T cell therapy: a case report"],"prefix":"10.1177","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-9151-4139","authenticated-orcid":false,"given":"Vincent","family":"Sunder-Plassmann","sequence":"first","affiliation":[{"name":"Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria"},{"name":"Christian Doppler Laboratory for Personalized Immunotherapy, Department of Medicine I, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5490-2371","authenticated-orcid":false,"given":"Barbara","family":"Kiesewetter","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3248-5802","authenticated-orcid":false,"given":"Markus","family":"Raderer","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Medicine I, Medical University of Vienna, Waehringer Guertel 18-20, Vienna 1090, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,8,5]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.8.2780"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-05-282632"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23608"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01620-2"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2230"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023022353"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-019-0209-5"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25487"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1701769"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-03-635326"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18519"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02370"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024015014"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.87"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2025016315"},{"key":"e_1_3_4_17_2","first-page":"223","article-title":"The CARE guidelines: consensus-based clinical case reporting guideline development","volume":"7","author":"Gagnier JJ","year":"2013","unstructured":"Gagnier JJ, Kienle G, Altman DG, et al. The CARE guidelines: consensus-based clinical case reporting guideline development. BMJ Case Rep 2013; 7: 223.","journal-title":"BMJ Case Rep"},{"issue":"3","key":"e_1_3_4_18_2","first-page":"576","article-title":"\u201cThe End of the Golden Weather\u201d: therapeutic strategies for mantle cell lymphoma relapsed or refractory to covalent BTK inhibitors","volume":"110","author":"Grainger BT","year":"2025","unstructured":"Grainger BT, Cheah CY. \u201cThe End of the Golden Weather\u201d: therapeutic strategies for mantle cell lymphoma relapsed or refractory to covalent BTK inhibitors. Haematologica 2025; 110(3): 576\u2013587.","journal-title":"Haematologica"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx020"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-198920"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-157679"},{"issue":"4","key":"e_1_3_4_22_2","first-page":"1194","article-title":"Polatuzumab vedotin plus bendamustine and rituximab or obinutuzumab in relapsed\/refractory follicular lymphoma: a phase Ib\/II study","volume":"109","author":"Flowers CR","year":"2024","unstructured":"Flowers CR, Matasar MJ, Herrera AF, et al. Polatuzumab vedotin plus bendamustine and rituximab or obinutuzumab in relapsed\/refractory follicular lymphoma: a phase Ib\/II study. Haematologica 2024; 109(4): 1194\u20131205.","journal-title":"Haematologica"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.3656"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14937"},{"issue":"5","key":"e_1_3_4_25_2","first-page":"413","article-title":"Quantitative analysis of CD79b, CD5 and CD19 in mature B-cell lymphoproliferative disorders","volume":"84","author":"Cabezudo E","year":"1999","unstructured":"Cabezudo E, Carrara P, Morilla R, et al. Quantitative analysis of CD79b, CD5 and CD19 in mature B-cell lymphoproliferative disorders. Haematologica 1999; 84(5): 413\u2013418.","journal-title":"Haematologica"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-021-04560-6"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01097"},{"issue":"1","key":"e_1_3_4_28_2","first-page":"343","article-title":"Final results and overall survival data from a phase II study of acalabrutinib monotherapy in patients with relapsed\/refractory mantle cell lymphoma, including those with poor prognostic factors","volume":"109","author":"Le Gouill S","year":"2024","unstructured":"Le Gouill S, D\u0142ugosz-Danecka M, Rule S, et al. Final results and overall survival data from a phase II study of acalabrutinib monotherapy in patients with relapsed\/refractory mantle cell lymphoma, including those with poor prognostic factors. Haematologica 2024; 109(1): 343\u2013350.","journal-title":"Haematologica"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-00690"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021014162"},{"issue":"1","key":"e_1_3_4_31_2","first-page":"92","article-title":"Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I\/II BRUIN trial","volume":"110","author":"Shah NN","year":"2025","unstructured":"Shah NN, Wang M, Roeker LE, et al. Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I\/II BRUIN trial. Haematologica 2025; 110(1): 92\u2013102.","journal-title":"Haematologica"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvaf095"}],"container-title":["Therapeutic Advances in Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17588359261472319","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17588359261472319","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17588359261472319","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:30:17Z","timestamp":1786120217000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17588359261472319"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":31,"alternative-id":["10.1177\/17588359261472319"],"URL":"https:\/\/doi.org\/10.1177\/17588359261472319","relation":{},"ISSN":["1758-8359","1758-8359"],"issn-type":[{"value":"1758-8359","type":"print"},{"value":"1758-8359","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8]]},"article-number":"17588359261472319"}}